| 引用本文:金金1,2，吕健1，王志飞1，谢雁鸣1，孙梦华1.感咳双清胶囊治疗急性上呼吸道感染有效性与安全性的系统评价与Meta分析[J].世界中医药,2020,(01):. |
|
| 感咳双清胶囊治疗急性上呼吸道感染有效性与安全性的系统评价与Meta分析 |
| Effectiveness and Safety of Ganke Shuangqing Capsule for Acute Upper Respiratory Tract Infection:A Systematic Review and Meta-analysis |
| 投稿时间：2019-12-10 |
| DOI：10.3969/j.issn.1673-7202.2020.01.005 |
| 中文关键词: 感咳双清胶囊 利巴韦林 常规治疗 急性上呼吸道感染 有效性 系统评价 Meta分析 随机对照试验 |
| English Keywords:Ganke Shuangqing Capsule Ribavirin Conventional treatment Acute upper respiratory tract infections Effectiveness Systematic review Meta-analysis Randomized controlled trial |
| 基金项目:国家重点研发计划项目（2018YFC1707400）；国家重点研发计划课题（2018YFC1707410） |
|
| 摘要点击次数: 391 |
| 全文下载次数: 0 |
| 中文摘要: |
| 评价感咳双清胶囊治疗急性上呼吸道感染的疗效和安全性。本研究系统检索了中国期刊全文数据库(CNKI)、万方数据库(WanFang)、中国生物医学文献数据库(CBM)、维普资讯中文科技期刊数据库(VIP)、Medline、EMbase、Cochrane Library、Web of Science，收集感咳双清胶囊治疗急性上呼吸道感染的随机对照试验，检索时间为该数据库建库至2019年5月，采用RenMan5.3软件进行Meta分析。结局的效应指标采用相对危险度(RR)或均数差(MD)，均以95%可信区间表示。本研究共纳入7项随机对照试验，涉及1 633例患者。Meta分析结果显示:在常规治疗的基础上，感咳双清胶囊治疗急性上呼吸道感染临床总有效率优于利巴韦林[RR=1.16，95%CI=(1.12，1.21)，P<0.000 01]；单用感咳双清胶囊临床总有效率优于单用利巴韦林[RR=1.18，95%CI=(1.01，1.37)，P=0.04]；在治疗伴发热患者的疾病有效率上，感咳双清胶囊联合常规治疗疗效优于利巴韦林联合常规治疗[RR=1.16，95%CI=(1.07，1.26)，P=0.000 5]；感咳双清胶囊联合常规治疗在缩短鼻塞持续时间[MD=-0.80，95%CI=(-0.91，-0.69)，P<0.000 01]与疾病总病程[MD=-1.23，95%CI=(-1.58，-0.88)，P<0.000 01]疗效均优于利巴韦林联合常规治疗。感咳双清胶囊在治疗急性上呼吸道感染过程中不良反应轻微。综上所述，在常规治疗的基础上，感咳双清胶囊治疗急性上呼吸道感染总体疗效优于利巴韦林。但上述结论尚需更多高质量的研究进行验证。 |
| English Summary: |
| To systematically review the efficacy and safety of Ganke Shuangqing Capsules for acute upper respiratory tract infections. Articles published before May 2019 were searched from CNKI, WanFang, VIP, CBM, MEDLINE, EmBase, Cochrane library, Web of Science. These articles were randomize controlled trials(RCTs)which took Ganke Shuangqing Capsules as the main intervention measure. Articles data were analyzed by RenMan5.3 software. Analyzed outcomes were shown as relative risk(RR)or mean difference(MD)and its 95% confidence interval(CI). 7 RCTs involving 1 633 patients were included totally. Meta-analysis showed that Ganke Shuangqing Capsules improved clinical effectiveness in acute upper respiratory tract infection [RR=1.16, 95%CI=(1.12, 1.21), P<0.000 01] on the basis of usual care when compared with ribavirin plus usual care. The clinical total effective rate of Ganke Shuangqing Capsule alone was better than ribavirin alone [RR=1.18, 95% CI=(1.01, 1.37), P=0.04]; In the aspect of the people with fever's effectiveness, the difference between Ganke Shuangqing Capsules plus usual care compared with ribavirin plus usual care had statistically significant difference [RR=1.16, 95%CI=(1.07, 1.26), P=0.000 5]. It was also statistically significant in the aspects of shorting during of stuffy running nose [MD=-0.80, 95%CI=(-0.91，-0.69), P<0.000 01] and the course duration [MD=-1.23, 95%CI=(-1.58，-0.88), P<0.000 01]. Ganke Shuangqing Capsule had mild side effects during the treatment of acute upper respiratory tract infection. In a word, the whole effectiveness of Ganke Shuangqing Capsules for acute upper respiratory tract infections was better than ribavirin. However, this conclusion needs more high quality study to confirm. |
| 查看全文 查看/发表评论 下载PDF阅读器 |
|
|
|
